Tonix Pharmaceuticals Azioni (NASDAQ: TNXP)

Ultime notizie per Tonix Pharmaceuticals (NASDAQ:TNXP) Azioni

Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

Elevate,Healthcare,With,Ai,Technology,Services.virtual,Health,Care,Analytics,Empower

News

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

ARQT

TNXP

L&#39;analisi tecnica rivela segnali di allarme per queste società: cosa devono aspettarsi gli investitori e perché è importante agire.

2 titoli del settore sanitario che potrebbero crollare questo trimestre

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals Holding Corp

Shares of Tonix Pharmaceuticals Holding Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) are trading lower by 6.8% to $26.83 during Thursday&#8217;s session, potentially pulling back on profit-taking, after surging around 60% this week <a href="https://www.benzinga.com/news/25/03/44457827/why-tonix-pharmaceuticals-tnxp-stock-is-rising">following a regulatory update</a> on its experimental fibromyalgia treatment, TNX-102 SL.
What To Know: Tonix announced on Tuesday that the FDA will not require an Advisory Committee meeting for its New Drug Application for TNX-102 SL, removing a potential roadblock in the approval process. This decision brings the company one step closer to a potential Q4 2025 launch, pending final FDA approval.
Read Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/03/44514663/whats-going-on-with-cava-group-stock-thursday">What&#8217;s Going On With Cava Group Stock Thursday?</a> CEO Seth Lederman emphasized the drug&#8217;s potential to introduce a new class of fibromyalgia treatments, offering hope to millions of patients struggling with this chronic pain disorder.
TNX-102 SL is a sublingual formulation of cyclobenzaprine HCl, designed to improve symptom management in fibromyalgia patients. The drug was granted Fast Track designation in 2024, expediting its regulatory review.
Tonix says the company remains optimistic about the drug's potential to provide a new, effective treatment option for patients seeking relief.
Read Also: <a href="https://www.benzinga.com/markets/25/03/44509733/gm-ford-tesla-and-other-auto-stocks-slide-in-thursday-pre-market-whats-going-on">GM, Ford, Tesla And Other Auto Stocks Slide In Thursday Pre-Market: What&#8217;s Going On?</a>
<h2 class="wp-block-heading">How To Buy TNXP Stock</h2>
By now you're likely curious about how to participate in the market for Tonix Pharmaceuticals &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of Tonix Pharmaceuticals, which is trading at $25.76 as of publishing time, $100 would buy you 3.88 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, TNXP has a 52-week high of $1,146.01 and a 52-week low of $6.76.

What's Going On With Tonix Pharmaceuticals (TNXP) Stock?

As of March 25, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Arcutis Biotherapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>)</h3>
<ul>
<li>Health Canada, on March 17, approved its Zoryve cream for the treatment of mild to moderate atopic dermatitis. This approval comes after data from phase 3 clinical trials showed that 90% of patients experienced symptom improvement within four weeks and 69% achieved at least a 50% reduction in disease severity. The company's stock gained around 42% over the past month and has a <a href="https://www.benzinga.com/quote/ARQT">52-week high of $17.70</a>.</li>
<li>RSI Value: 71&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>ARQT Price Action: Shares of Arcutis Biotherapeutics gained 1.7% to close at $17.29 on Monday.</li>
</ul>
<h3 class="wp-block-heading">Tonix Pharmaceuticals Holding Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>)</h3>
<ul>
<li>On March 24, Tonix Pharmaceuticals Holding announced that the FDA will not require an Advisory Committee meeting for its New Drug Application for TNX-102 SL, a potential new treatment for fibromyalgia. The company's stock gained around 279% over the past month and <a href="https://www.benzinga.com/quote/TNXP">has a 52-week high </a>of $1,145.92.</li>
<li>RSI Value: 77.1</li>
<li>TNXP Price Action: Shares of Tonix Pharmaceuticals gained 32.5% to close at $30.51 on Monday. </li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/03/44457888/top-2-financial-stocks-that-may-fall-off-a-cliff-in-march">Top 2 Financial Stocks That May Fall Off A Cliff In March</a></li>
</ul>

Top 2 Health Care Stocks That Are Ticking Portfolio Bombs

<h3>Gainers</h3>
<ul>
<li>Capstone Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPS#NASDAQ">CAPS</a>) shares moved upwards by 75.6% to $3.02 during Monday's regular session. The market value of their outstanding shares is at $4.2 million. </li>
<li>Kindly MD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>) stock rose 57.28% to $2.38. The company's market cap stands at $14.1 million. </li>
<li>Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) stock rose 26.24% to $29.07. The company's market cap stands at $187.0 million. As per the news, the Q4 earnings report came out 4 days ago. </li>
<li>Lexeo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXEO#NASDAQ">LXEO</a>) shares moved upwards by 23.57% to $3.35. The company's market cap stands at $110.7 million. As per the news, the Q4 earnings report came out today. </li>
<li>CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) stock rose 23.55% to $7.03. The market value of their outstanding shares is at $350.8 million. </li>
<li>Oncology Institute (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOI#NASDAQ">TOI</a>) stock moved upwards by 22.81% to $1.22. The market value of their outstanding shares is at $92.4 million. The company's, Q4 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>23andMe Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ME#NASDAQ">ME</a>) shares declined by 52.1% to $0.86 during Monday's regular session. The company's market cap stands at $23.0 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) stock fell 40.18% to $0.67. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) shares declined by 31.08% to $3.42. The company's market cap stands at $39.3 million. </li>
<li>Unity Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBX#NASDAQ">UBX</a>) shares declined by 30.96% to $1.26. The company's market cap stands at $21.2 million. </li>
<li>Aditxt (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTX#NASDAQ">ADTX</a>) stock declined by 25.81% to $7.14. The market value of their outstanding shares is at $7.3 million. </li>
<li>CervoMed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) stock decreased by 24.64% to $10.77. The company's market cap stands at $93.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ADTX

CAPS

CRVO

CYRX

KDLY

LXEO

RNAZ

12 Health Care Stocks Moving In Monday's Intraday Session

Tonix Pharmaceuticals Holding Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) shares are trading higher by 25.3% to $28.85 during Monday&#8217;s session after the company announced that the FDA <a href="https://www.benzinga.com/pressreleases/25/03/g44455533/tonix-pharmaceuticals-announces-that-fda-will-not-require-an-advisory-committee-meeting-to-discuss">will not require</a> an Advisory Committee meeting for its New Drug Application for TNX-102 SL, a potential new treatment for fibromyalgia.
What To Know: CEO Seth Lederman expressed confidence in the drug's potential to introduce a new class of fibromyalgia treatments. The company anticipates a possible launch in Q4 2025, pending FDA approval. 
TNX-102 SL, a sublingual formulation of cyclobenzaprine HCl, previously received Fast Track designation in 2024, expediting its regulatory review.
Tonix says, with over 10 million U.S. adults affected by fibromyalgia, the approval of TNX-102 SL could mark a significant advancement in addressing this chronic pain disorder. Tonix remains optimistic about the drug's potential to meet the unmet needs of fibromyalgia patients.
Read Also: <a href="https://www.benzinga.com/markets/25/03/44455074/oil-rises-as-us-and-russia-begin-talks-in-saudi-arabia-for-ukraine-ceasefire-black-sea-deal">Oil Rises As US And Russia Begin Talks In Saudi Arabia For Ukraine Ceasefire, Black Sea Deal</a>
<h2 class="wp-block-heading">How To Buy TNXP Stock</h2>
By now you're likely curious about how to participate in the market for Tonix Pharmaceuticals &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of Tonix Pharmaceuticals, which is trading at $23.03 as of publishing time, $100 would buy you 4.34 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, TNXP has a 52-week high of $1,146.01 and a 52-week low of $6.76.

Why Tonix Pharmaceuticals (TNXP) Stock Is Rising

WIIM

Tonix Pharmaceutical shares are trading higher after the company announced the FDA will not require an advisory committee for Tnx-102 SL.

General

Tonix Pharmaceuticals Announces That FDA Will Not Require An Advisory Committee Meeting To Discuss The Company's New Drug Applicatio For Tnx-102 Sl For The Management Of Fibromyalgia; If Approved, Tnx-102 Sl (cyclobenzaprine Hcl Sublingual Tablets) Would Be The First New Treatment Option For Fibromyalgia Patients In 15 Years

<h3>Gainers</h3>
<ul>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock increased by 98.1% to $4.12 during Friday's regular session. The company's market cap stands at $47.4 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) stock moved upwards by 60.9% to $1.24. </li>
<li>Galecto (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLTO#NASDAQ">GLTO</a>) shares increased by 40.09% to $5.8. The market value of their outstanding shares is at $7.6 million. As per the press release, Q4 earnings came out 2 days ago. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock increased by 30.36% to $58.67. The market value of their outstanding shares is at $763.4 million. </li>
<li>Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) stock moved upwards by 26.71% to $23.05. The company's market cap stands at $128.8 million. As per the news, the Q4 earnings report came out 3 days ago. </li>
<li>CervoMed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) shares moved upwards by 21.49% to $14.04. The market value of their outstanding shares is at $115.9 million. As per the press release, Q4 earnings came out 4 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>TC BioPharm (Holdings) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) stock fell 62.1% to $0.58 during Friday's regular session. The company's market cap stands at $5.9 million. </li>
<li>TELA Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELA#NASDAQ">TELA</a>) shares decreased by 38.47% to $1.44. The market value of their outstanding shares is at $56.7 million. As per the press release, Q4 earnings came out yesterday. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) shares declined by 31.95% to $0.28. The market value of their outstanding shares is at $2.9 million. </li>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) stock declined by 23.4% to $1.67. The market value of their outstanding shares is at $1.2 million. </li>
<li>Monopar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNPR#NASDAQ">MNPR</a>) shares decreased by 16.92% to $37.17. The company's market cap stands at $226.8 million. </li>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) shares fell 14.53% to $0.22. The company's market cap stands at $1.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GCTK

GLTO

MNPR

STSS

TCBP

TELA

WINT

12 Health Care Stocks Moving In Friday's Intraday Session

Noble Capital Markets analyst Robert LeBoyer reiterates Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) with a Outperform and maintains $70 price target.

Price Target

Reiteration

Analyst Ratings

Noble Capital Markets Reiterates Outperform on Tonix Pharmaceuticals, Maintains $70 Price Target

<h3>Gainers</h3>
<ul>
<li>Black Diamond Therapeutic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDTX#NASDAQ">BDTX</a>) stock moved upwards by 29.1% to $2.17 during Wednesday's regular session. The company's market cap stands at $122.9 million. </li>
<li>Lyell Immunopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYEL#NASDAQ">LYEL</a>) shares moved upwards by 23.13% to $0.6. The company's market cap stands at $175.8 million. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares moved upwards by 22.58% to $2.47. The market value of their outstanding shares is at $1.6 million. </li>
<li>TuHURA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HURA#NASDAQ">HURA</a>) shares moved upwards by 17.85% to $3.3. The company's market cap stands at $139.5 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) stock moved upwards by 17.37% to $3.35. The company's market cap stands at $2.2 million. </li>
<li>Scienture Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNX#NASDAQ">SCNX</a>) stock rose 16.98% to $1.86. The market value of their outstanding shares is at $16.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) shares fell 19.9% to $16.45 during Wednesday's regular session. The company's market cap stands at $91.9 million. The company's, Q4 earnings came out yesterday. </li>
<li>Intensity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTS#NASDAQ">INTS</a>) stock decreased by 17.91% to $1.88. The market value of their outstanding shares is at $28.5 million. As per the press release, Q4 earnings came out 4 days ago. </li>
<li>HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) stock declined by 17.54% to $83.84. The market value of their outstanding shares is at $7.2 billion. As per the press release, Q4 earnings came out yesterday. </li>
<li>Can Fite Biofarma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CANF#AMEX">CANF</a>) stock decreased by 16.84% to $1.68. The company's market cap stands at $8.3 million. </li>
<li>OmniAb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OABI#NASDAQ">OABI</a>) shares decreased by 15.84% to $2.69. The market value of their outstanding shares is at $324.9 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>vTv Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTVT#NASDAQ">VTVT</a>) stock fell 14.49% to $17.95. The company's market cap stands at $46.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BDRX

BDTX

CANF

HURA

INTS

LYEL

OABI

SCNX

VERO

VTVT

12 Health Care Stocks Moving In Wednesday's Intraday Session

Tonix Pharmaceuticals Holdings shares are trading lower after the company reported mixed Q4 financial results.

U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Wednesday.
Shares of Absci Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>) fell sharply in today's pre-market trading after the company reported <a href="https://www.benzinga.com/quote/ABSI/earnings">worse-than-expected fourth-quarter financial results.</a>
Absci reported quarterly losses of 25 cents per share which missed the analyst consensus estimate of 23 cents per share. This is unchanged from the same period last year. The company reported quarterly sales of $665.000 thousand which missed the analyst consensus estimate of $1.778 million.
Absci shares dipped 9.4% to $2.79 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares dipped 16.1% to $26.50 in pre-market trading after climbing 70% on Tuesday.</li>
<li>Turkcell Iletisim Hizmetleri A.S. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TKC#NYSE">TKC</a>) shares fell 14.8% to $6.43 in pre-market trading.</li>
<li>HealthEquity, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) shares declined 14.7% to $86.68 in pre-market trading after the company reported worse-than-expected quarterly earnings results.</li>
<li>Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) shares fell 13% to $17.87 in pre-market trading following weak quarterly sales.</li>
<li>Waterdrop Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WDH#NYSE">WDH</a>) declined 6.5% to $1.30 in pre-market trading following a 5% fall on Tuesday.</li>
<li>Resolute Holdings Management, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RHLD#NASDAQ">RHLD</a>) declined 4.3% to $34.53 in pre-market trading after dipping 18% on Tuesday.</li>
<li>Target Hospitality Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TH#NASDAQ">TH</a>) fell 3.8% to $5.63 in pre-market trading.</li>
<li>Alpha Technology Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATGL#NASDAQ">ATGL</a>) fell 3.2% to $31.47 in pre-market trading after gaining 14% on Tuesday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44375233/top-3-materials-stocks-which-could-rescue-your-portfolio-this-month">Top 3 Materials Stocks Which Could Rescue Your Portfolio This Month</a></li>
</ul>

ABSI

ATGL

RHLD

Absci Posts Downbeat Results, Joins HealthEquity, Tonix Pharmaceuticals And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Shares of StoneCo Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>) rose sharply in pre-market trading after the company reported better-than-expected fourth-quarter <a href="https://www.benzinga.com/quote/STNE/earnings">earnings and sales results</a>.
StoneCo shares jumped 8% to $10.64 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Leishen Energy Holding Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSE#NASDAQ">LSE</a>) gained 90% to $14.31 in pre-market trading after jumping over 46% on Tuesday. The company recently reported FY24 financial results.</li>
<li>Virpax Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) rose 35.4% to $0.1760 in pre-market trading after the company announced positive results from a beagle dog dose range-finding study.</li>
<li>TEN Holdings, Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XHLD#NASDAQ">XHLD</a>) gained 34% to $0.7839 in pre-market trading. TEN Holdings shares jumped 18% on Tuesday after the company announced a $1 million stock repurchase program.</li>
<li>Aterian, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATER#NASDAQ">ATER</a>) gained 27% to $2.68 in pre-market after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Bowen Acquisition Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOWN#NASDAQ">BOWN</a>) gained 24% to $5.43 in pre-market trading after jumping 5% on Tuesday.</li>
<li>CARGO Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGX#NASDAQ">CRGX</a>) gained 21.1% to $4.60 in pre-market trading after the company suspended CRG-023 &amp; allogeneic platform and initiated 90% workforce reduction.</li>
<li>Hillenbrand, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HI#NYSE">HI</a>) gained 17.3% to $29.29 in pre-market trading.</li>
<li>Intrusion Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTZ#NASDAQ">INTZ</a>) rose 11.8% to $1.32 in pre-market trading after dipping 23% on Tuesday.</li>
<li>CNS Pharmaceuticals, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) rose 10.4% to $3.92 after surging 16% on Tuesday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>FST Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KBSX#NASDAQ">KBSX</a>) fell 23.1% to $4.22 in pre-market trading after gaining 310% on Tuesday.</li>
<li>5E Advanced Materials, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEAM#NASDAQ">FEAM</a>) shares fell 21.2% to $3.08 in pre-market trading after gaining 5% on Tuesday.</li>
<li>Starbox Group Holdings Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STBX#NASDAQ">STBX</a>) fell 18.5% to $0.2012 in pre-market trading after gaining around 22% on Tuesday. Starbox Group company received staff determination notice from Nasdaq.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) declined 16.1% to $26.50 in pre-market trading after climbing 70% on Tuesday.</li>
<li>OSR Holdings, Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSRH#NASDAQ">OSRH</a>) dipped 15.5% to $1.51 in pre-market trading after jumping 34% on Tuesday.</li>
<li>Turkcell Iletisim Hizmetleri A.S. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TKC#NYSE">TKC</a>) shares tumbled 14.8% to $6.43 in pre-market trading.</li>
<li>HealthEquity, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) shares fell 14.7% to $86.68 in pre-market trading after the company reported worse-than-expected quarterly earnings results.</li>
<li>Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) shares dipped 13% to $17.87 in pre-market trading following weak quarterly sales.</li>
<li>Absci Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>) fell 9.4% to $2.79 in today's pre-market trading after the company reported worse-than-expected fourth-quarter financial results.</li>
<li>Waterdrop Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WDH#NYSE">WDH</a>) fell 6.5% to $1.30 in pre-market trading after declining around 5% on Tuesday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44375233/top-3-materials-stocks-which-could-rescue-your-portfolio-this-month">Top 3 Materials Stocks Which Could Rescue Your Portfolio This Month</a></li>
</ul>

ATER

BOWN

CNSP

CRGX

FEAM

INTZ

KBSX

OSRH

STBX

STNE

VRPX

XHLD

Why StoneCo Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket

Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) reported quarterly losses of $(9.77) per share which beat the analyst consensus estimate of $(291.74) by 96.65 percent. The company reported quarterly sales of $2.600 million which missed the analyst consensus estimate of $3.500 million by 25.71 percent. This is a 31.20 percent decrease over sales of $3.779 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Tonix Pharmaceuticals Q4 2024 GAAP EPS $(9.77) Beats $(291.74) Estimate, Sales $2.600M Miss $3.500M Estimate

<h3>Gainers</h3>
<ul>
<li>Syros Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRS#NASDAQ">SYRS</a>) shares increased by 49.0% to $0.13 during Tuesday's regular session. The market value of their outstanding shares is at $3.4 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock increased by 24.37% to $23.01. The company's market cap stands at $299.4 million. </li>
<li>Opus Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRD#NASDAQ">IRD</a>) shares increased by 20.0% to $1.13. The market value of their outstanding shares is at $35.6 million. </li>
<li>TuHURA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HURA#NASDAQ">HURA</a>) shares moved upwards by 19.85% to $2.9. The market value of their outstanding shares is at $122.6 million. </li>
<li>OSR Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSRH#NASDAQ">OSRH</a>) stock increased by 19.12% to $1.58. The market value of their outstanding shares is at $30.5 million. </li>
<li>Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) stock rose 18.67% to $19.32. The market value of their outstanding shares is at $108.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Avenue Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXI#NASDAQ">ATXI</a>) shares fell 47.2% to $0.45 during Tuesday's regular session. </li>
<li>Jaguar Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) stock decreased by 40.6% to $0.28. The company's market cap stands at $4.5 million. </li>
<li>Hyperfine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYPR#NASDAQ">HYPR</a>) shares declined by 27.76% to $0.92. The company's market cap stands at $71.6 million. The company's, Q4 earnings came out yesterday. </li>
<li>Gyre Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GYRE#NASDAQ">GYRE</a>) stock fell 26.51% to $9.03. The company's market cap stands at $774.5 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) shares fell 23.2% to $0.13. The market value of their outstanding shares is at $2.3 million. </li>
<li>Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) shares declined by 20.82% to $80.25. The company's market cap stands at $7.6 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATXI

GYRE

HYPR

JAGX

SRPT

SYRS

12 Health Care Stocks Moving In Tuesday's Intraday Session

The World Health Organization (WHO) recently reaffirmed the spread of new clade Ib Mpox a public health emergency of international concern (PHEIC): second Mpox-related WHO PHEIC declaration in two years
Clade Ib Mpox cases detected in several countries in Central and Eastern Africa as well as China, Thailand, Singapore, India, England, parts of Europe and the Middle East, Canada and the United States
Tolerability of TNX‐801 vaccination in immune-compromised animal models supports clinical development
CHATHAM, N.J., March 10, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced it has been awarded a grant from the Medical CBRN Defense Consortium (MCDC) to support the development of TNX-801 (recombinant horsepox virus, live vaccine). MCDC is a consortium of industrial, academic, and non-profit entities that supports the U.S. government in meeting military requirements for medical products to protect against chemical, biological, radiological and nuclear (CBRN) threats. TNX-801 is in development as an mpox and smallpox vaccine with the potential to be delivered via innovative alternative methods to improve patient compliance, ease of use and tolerability. The MCDC grant will allow for further comprehensive market analyses, target market identification and commercialization planning, including for both private and government markets.
"We are excited by the opportunity to collaborate with MCDC and are thankful for their support of our vaccine candidate," said Seth Lederman, M.D., President, and Chief Executive Officer of Tonix. "TNX-801 offers an appealing target product profile, requiring just a single dose for durable, long-term protection, with favorable shipping and storage requirements. With a significant global unmet need, TNX-801 is in a strong position to make a potential impact towards preventing mpox and controlling mpox epidemics."

Biotech

Tonix Pharmaceuticals Receives Grant By Medical CBRN Defense Consortium For Development Of TNX-801, Company's Single-Dose Mpox And Smallpox Vaccine Candidate

Tonix Pharmaceuticals Holding Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) shares have surged 115% to $16.85 since Monday's open, driven by a series of key business updates this week.
What To Know: Tonix this week <a href="https://www.benzinga.com/pressreleases/25/03/g44104557/tonix-pharmaceuticals-presented-data-and-analyses-of-tnx-102-sl-treatment-effects-on-fibromyalgia-">announced data</a> regarding its fibromyalgia treatment, TNX-102 SL, presenting Phase 3 data at the 7th International Congress on Controversies in Fibromyalgia. 
The study showed that the sublingual formulation demonstrated a statistically significant improvement in the primary endpoint of reduction in fibromyalgia pain reduced pain. The U.S. FDA has set an August 15, 2025, Prescription Drug User Fee Act (PDUFA) goal date for potential marketing approval.
Tonix also announced the appointment of Siobhan Fogarty as Chief Technical Officer and <a href="https://www.benzinga.com/pressreleases/25/03/g44137620/tonix-pharmaceuticals-to-present-at-the-2025-virtual-investor-summit">confirmed</a> COO Jessica Morris will present at the 2025 Virtual Investor Summit on March 11.
Read Also: <a href="https://www.benzinga.com/news/global/25/03/44166916/whats-going-on-with-alibaba-stock-thursday-6">What&#8217;s Going On With Alibaba Stock Thursday?</a>
<h2 class="wp-block-heading">How To Buy TNXP Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Tonix Pharmaceuticals&#8217; case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, TNXP has a 52-week high of $1,216.00 and a 52-week low of $6.76.

Tonix Pharmaceuticals (TNXP) Stock Is Up 115% This Week: What's Going On?

<ul>
<li>TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for transmucosal delivery and durable activity in treating fibromyalgia</li>
<li>TNX-102 SL demonstrated statistically significant improvement in the primary endpoint of reduction in fibromyalgia pain in two double-blind randomized Phase 3 studies</li>
<li>FDA Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025, for TNX-102 SL for the management of fibromyalgia</li>
<li>If approved by FDA, it would become the first member of a new class of non-opioid analgesic drugs for fibromyalgia and the first new drug for treating fibromyalgia in more than 15 years</li>
</ul>

Tonix Pharmaceuticals Presents Phase 3 Data On TNX-102 SL For Fibromyalgia At International Congress

Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) shares are moving higher on Friday after the company provided preliminary 2024 <a href="https://www.benzinga.com//node/43559033">fiscal-year financial results</a>.
What To Know: The company reported net revenue of $10.1 million, compared to $7.8 million for the prior year. In addition, it reported $98.8 million in cash and cash equivalents as of the end of 2024.
Tonix expects its cash reserves, along with approximately $30.4 million in gross proceeds from 2025 first-quarter sales, to sustain operations through the 2026 first quarter. The cash runway is expected to cover operations past the Food and Drug Administration&#8217;s August 15th goal date for a decision on marketing authorization for TNX-102 SL for fibromyalgia management. The company is now debt-free after repaying a mortgage with JGB Capital on February 3.
 Additionally, it reported capital expenditures of $0.1 million, compared $29.1 million for the prior year.
Lastly, Tonix reported a net operating loss of $126.6 million, compared to a net operating loss of $116.7 million for the prior year.
See Also: <a href="https://www.benzinga.com/25/02/43564020/consumer-sentiment-sinks-economist-flags-unusually-large-rise-in-inflation-perception">Consumer Sentiment Sinks In February: Economist Flags &#8216;Unusually Large&#8217; Rise In Inflation Perception</a>
TNXP Price Action: At the time of writing, Tonix shares are trading 14.8% higher at $12.90, per data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: via Shutterstock

What's Going On With Tonix Pharmaceuticals Shares Friday?

Tonix Pharmaceutical shares are trading higher after the company provided preliminary Q4 financial results.

Preliminary Full Year 2024 Financial Results1
<ul>
<li>The Company had approximately $98.8 million in cash and cash equivalents as of December 31, 2024.</li>
<li>Net cash used in operating activities was approximately $60.9 million, compared to $102.0 million for the prior year.</li>
<li>Capital expenditures was approximately $0.1 million, compared to $29.1 million for the prior year.</li>
<li>Net operating loss was approximately $126.6 million, which includes non-cash impairment charges of approximately $59.0 million, compared to net operating loss of $116.7 million for the prior year.</li>
<li>The Company announced that net revenue from the sale of its marketed products was approximately $10.1 million, compared to $7.8 million for the prior year.</li>
<li>On February 3, 2025, the Company repaid a mortgage (Loan and Guaranty Agreement) with JGB Capital and related parties that was secured by two facilities and the Company is now debt-free.</li>
</ul>
The Company expects that its cash resources at December 31, 2024, and the gross proceeds of approximately $30.4 million raised from sales under its at-the-market facility in the first quarter of 2025, will be sufficient to fund its planned operations into the first quarter of 2026.

Guidance

Tonix Pharmaceuticals Reports FY24 Preliminary Financials: $98.8M In Cash And Cash Equivalents As Of December 31, 2024, Revenue Hits ~$10.1M Vs $7.8M YoY

Health Care

Press Releases

Tonix Pharmaceuticals to Present at the Zacks SCR Life Sciences Virtual Investor Forum on March 13th

Tonix's TNX-1500 Shows Promise in Preventing Organ Transplant Rejections of Either Human or Pig Organs; Autoimmune Diseases Also a Target

Life Sciences Investor Forum Agenda Announced for March 13th

Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring 2025

Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing

Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

As Mpox Cases Spread Around the World, Tonix Pharmaceuticals' Single-Dose Vaccine TNX-801 Has Potential to Slow the Spread

Tonix Pharmaceuticals Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for TNX-102 SL for the Management of Fibromyalgia

Tonix Pharmaceuticals Announces Presentation at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting

Tonix's Experimental Non-Opioid Analgesic Treatment for Fibromyalgia Could Start Bringing Relief Later This Year

AVCNF

BPTSY

CGTX

COCP

CSE:IZO

CSE:TELI

FBLG

HMTXF

IZOZF

LADX

NGENF

PDSB

RAFA

TELIF

TSX:AVCN

TSXV:HEM

TSXV:NGEN

Actuate Therapeutics, Inc. - Common stock

Actuate Therapeutics

Alector

C4 Therapeutics

Cellectis S.A. - American Depositary Shares

Cellectis

DBV Technologies S.A. - American Depositary Shares

DBV Technologies

Elicio Therapeutics

Enanta Pharmaceuticals, Inc. - Common Stock

Enanta Pharma

Greenwich LifeSciences, Inc. - Common stock

Greenwich LifeSciences

Genelux

TuHURA Biosciences

Inventiva S.A. - American Depository Shares

Inventiva

Kodiak Sciences

Lineage Cell Therapeutics, Inc. Common Stock

Lineage Cell Therapeutics

Larimar Therapeutics, Inc. - Common Stock

Larimar Therapeutics

Lexeo Therapeutics

Seres Therapeutics

Nkarta

Puma Biotechnology

ProKidney Corp. - Class A Ordinary Shares

ProKidney

Regulus Therapeutics

Sera Prognostics, Inc. - Class A Common Stock

Sera Prognostics

Sagimet Biosciences Inc. - Series A Common Stock

Sagimet Biosciences

Instil Bio

Tiziana Life Sciences Ltd - Common Shares

Tiziana Life Sciences

Zentalis Pharmaceuticals, Inc. - common stock

Zentalis Pharma

Noble Capital Markets

Alliance Global Partners

Dawson James

Untitled design - 2025-03-31T165341.547

VRTX

Tonix&#39;s Experimental Non-Opioid Analgesic Treatment For Fibromyalgia Could Start Bringing Relief Later This Year

Screenshot 2025-03-19 at 8.55.22 PM

BVNKF

As Mpox Cases Spread Around The World, Tonix Pharmaceuticals&#39; Single-Dose Vaccine TNX-801 Has Potential To Slow The Spread

Screenshot 2025-03-12 at 4.47.01 PM

AMGN

BIIB

ELDN

Tonix&#39;s TNX-1500 Shows Promise In Preventing Organ Transplant Rejections Of Either Human Or Pig Organs; Autoimmune Diseases Also A Target

Untitled design - 2024-12-07T011441.837

Tonix&#39;s TNX 102-SL Could Offer New Hope Of Pain Relief Without Narcotics For Fibromyalgia Sufferers

Screenshot 2024-11-13 at 11.54.41 PM

ABBV

Tonix Pharmaceuticals Targets Rapid Migraine Relief With Non-Oral Treatments

Screenshot 2024-09-30 at 9.13.36 PM

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-09-18 at 12.30.33 AM

New Hope For Mpox? How TNX-801 Could Meet The WHO&#39;s Vaccine Targets For A Safer, Single-Dose Solution

Untitled design - 2024-09-04T162950.621

As Research Into Pain Accelerates, A Newly Recognized Type Of Pain Comes To The Forefront – Tonix Targets It With FDA-Fast Track-Designated TNX-102 SL

Screenshot 2024-08-23 at 3.09.59 AM

Modern Twist To Centuries-Old Smallpox Vaccine Could Be Poised To Combat Deadly Mpox Strain As WHO Declares Global Emergency

Comments

Tonix Pharmaceuticals

Notizie

Ultime notizie per Tonix Pharmaceuticals (NASDAQ:TNXP) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO